AstraZeneca Says High-level Results From BATURA Phase 3b Trial Showed Airsupra (Albuterol/Budesonide) Met The Primary Endpoint, Demonstrating A Statistically Significant And Clinically Meaningful Reduction In The Risk Of A Severe Exacerbation When...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.